$NVCR stock has now risen 22% today, according to our price data from Polygon. There has been approximately $21,085,255 of trading volume.
Here is what we see in our data on $NVCR (you can track the company live on Quiver's $NVCR stock page):
$NVCR Insider Trading Activity
$NVCR insiders have traded $NVCR stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $NVCR stock by insiders over the last 6 months:
- MUKUND PARAVASTHU (Chief Operating Officer) has made 0 purchases and 2 sales selling 48,623 shares for an estimated $667,213.
- URI WEINBERG (Chf Medical and Innovation Ofr) has made 0 purchases and 3 sales selling 17,145 shares for an estimated $232,177.
- CHRISTOPH BRACKMANN (Chief Financial Officer) sold 6,412 shares for an estimated $85,314
- FRANK X LEONARD (Chief Executive Officer) sold 5,607 shares for an estimated $74,603
- MICHAL NATH PURI (Chief Human Resources Officer) sold 1,100 shares for an estimated $14,635
- NICOLAS LEUPIN (Former Chief Medical Officer) sold 1,100 shares for an estimated $14,635
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$NVCR Hedge Fund Activity
We have seen 131 institutional investors add shares of $NVCR stock to their portfolio, and 114 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,555,996 shares (-95.3%) from their portfolio in Q4 2025, for an estimated $58,909,028
- MORGAN STANLEY added 4,153,741 shares (+453.4%) to their portfolio in Q4 2025, for an estimated $53,707,871
- CAPITAL WORLD INVESTORS removed 2,000,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $25,860,000
- JACOBS LEVY EQUITY MANAGEMENT, INC added 1,121,192 shares (+1093.2%) to their portfolio in Q4 2025, for an estimated $14,497,012
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,114,207 shares (-11.6%) from their portfolio in Q4 2025, for an estimated $14,406,696
- MARSHALL WACE, LLP removed 1,034,978 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $13,382,265
- SG AMERICAS SECURITIES, LLC added 966,735 shares (+346.7%) to their portfolio in Q1 2026, for an estimated $10,537,411
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$NVCR Government Contracts
We have seen $10,704,262 of award payments to $NVCR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROSTHETICS. OPTUNE DEVICE.: $99,497
- PROSTHETIC - OPTUNE CANCER TREATMENT: $99,497
- PROS TRANSDUCERS: $99,497
- OPTUNE TRANSDUCER (6 MONTH RENTAL): $99,497
- OPTUNE PLUS TRANSDUCERS: $99,497
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
$NVCR Analyst Ratings
Wall Street analysts have issued reports on $NVCR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/12/2026
To track analyst ratings and price targets for $NVCR, check out Quiver Quantitative's $NVCR forecast page.
$NVCR Price Targets
Multiple analysts have issued price targets for $NVCR recently. We have seen 2 analysts offer price targets for $NVCR in the last 6 months, with a median target of $33.5.
Here are some recent targets:
- David Nierengarten from Wedbush set a target price of $18.0 on 04/16/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $49.0 on 02/26/2026
You can track data on $NVCR on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
